Could tailored blood thinner dosing prevent strokes in chinese patients?

NCT ID NCT05378035

First seen Jul 30, 2026 · Last updated Jul 31, 2026 · Updated 1 time

Summary

This study looks at how blood levels of common blood thinners (apixaban, dabigatran, edoxaban, and rivaroxaban) change over time in Chinese patients with atrial fibrillation. Researchers will take blood samples before and after stopping the medication for medical procedures. The goal is to understand why some patients may have higher risks of stroke or bleeding and to guide safer, more personalized treatment.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance
blood tests to measure levels of direct oral anticoagulants (apixaban, dabigatran, edoxaban, rivaroxaban)
What this could lead to
If successful, this could lead to safer, more personalized dosing of blood thinners for Chinese patients with atrial fibrillation, reducing the risk of strokes and bleeding.
What could go wrong
This is an observational study, not a treatment trial, so it will not directly test a new therapy. The findings may not apply to other ethnic groups or all patients.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ARTERIAL THROMBOEMBOLISM are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • Chinese University of Hong Kong

    RECRUITING

    Hong Kong, Hong Kong

More trials for these conditions

Other studies related to the condition(s) this trial covers.